Evidence map›Paper›PMID 38947039›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study.

Irene Bagala, Jane Frances Namuganga, Patience Nayebare, Gloria Cuu, Thomas Katairo, Isaiah Nabende, Samuel Gonahasa, Martha Nassali, Stephen Tukwasibwe, Grant Dorsey and 7 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Irene BagalaMakerere University College of Health Sciences, Kampala, Uganda.
Jane Frances NamugangaInfectious Diseases Research Collaboration, Kampala, Uganda.
Patience NayebareInfectious Diseases Research Collaboration, Kampala, Uganda.
Gloria CuuInfectious Diseases Research Collaboration, Kampala, Uganda.
Thomas KatairoInfectious Diseases Research Collaboration, Kampala, Uganda.
Isaiah NabendeInfectious Diseases Research Collaboration, Kampala, Uganda.
Samuel GonahasaInfectious Diseases Research Collaboration, Kampala, Uganda.
Martha NassaliInfectious Diseases Research Collaboration, Kampala, Uganda.
Stephen TukwasibweInfectious Diseases Research Collaboration, Kampala, Uganda.
Grant DorseyUniversity of California, San Francisco, USA.
Joaniter NankabirwaMakerere University College of Health Sciences, Kampala, Uganda.
Sabrina Bakeera KitakaMakerere University College of Health Sciences, Kampala, Uganda.
Sarah KiguliMakerere University College of Health Sciences, Kampala, Uganda.
Bryan GreenhouseUniversity of California, San Francisco, USA.
Isaac SsewanyanaInfectious Diseases Research Collaboration, Kampala, Uganda.
Moses R KamyaMakerere University College of Health Sciences, Kampala, Uganda.
Jessica BriggsUniversity of California, San Francisco, USA.

Funding

Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Improving the accuracy of malaria surveillance with serology and parasite genetic dataK23AI166009 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jessica Briggs · 2022 to 2026
$955k
Translational Studies of Plasmodium Falciparum Infection DynamicsK23AI076614 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENHOUSE, BRYAN R · 2008 to 2012
$609k
FIC NIH HHS D43 TW010526NIAID NIH HHS K23 AI076614NIAID NIH HHS K23 AI166009NIAID NIH HHS K24 AI144048
6 · The paper itself

Abstract

Background: Understanding COVID-19's impact on children is vital for public health policy, yet age-specific data is scarce, especially in Uganda. This study examines SARS-CoV-2 seroprevalence and risk factors among Ugandan children at two timepoints, along with COVID-19-related knowledge and practices in households, including adult vaccination status. Methods: Baseline surveys were conducted in 12 communities from April to May 2021 (post-Alpha wave) and follow-up surveys in 32 communities from November 2021 to March 2022 (Omicron wave). Household questionnaires and blood samples were collected to test for malaria by microscopy and for SARS-CoV-2 using a Luminex assay. Seroprevalence was estimated at both the survey and community level. Mixed-effects logistic regression models assessed the association between individual and household factors and SARS-CoV-2 seropositivity in children, adjusting for household clustering. Results: More households reported disruptions in daily life at baseline compared to follow-up, though economic impacts lingered. By the follow-up survey, 52.7% of adults had received at least one COVID-19 vaccine dose. Overall seroprevalence in children was higher at follow-up compared to baseline (71.6% versus 19.2%, p < 0.001). Seroprevalence in children ranged across communities from 6-37% at baseline and 50-90% at follow-up. At baseline, children from the poorest households were more likely to be infected. Increasing age remained the only consistent risk factor for SARS-CoV-2 seroconversion at both timepoints. Conclusions: Results indicate that a larger number of children were infected by the Delta and Omicron waves of COVID-19 compared to the Alpha wave. This study is the largest seroprevalence survey in children in Uganda, providing evidence that most children were infected with SARS-CoV-2 before the vaccine was widely available to pediatric populations. Pediatric infections were vastly underreported by case counts, highlighting the importance of seroprevalence surveys in assessing disease burden when testing and reporting rates are limited and many cases are mild or asymptomatic.

Indexed as

COVID-19COVID-19 risk factors in childrenCOVID-19 vaccinationSARS-CoV-2seroprevalenceserosurvey

Identifiers

PMID38947039
PMCPMC11213087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.